The month ahead: April’s upcoming events
AACR approaches, along with ASCO abstract titles.
Summit looks to repeat ivo's Chinese success
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
iTeos, and Roche's RAS mystery, start phase 1
First-in-human study listings include EOS-215 and RO7673396.
MediLink beats Sotio to the punch
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
Private biotechs and novel targets head for human trials
Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
J&J catches its menin rivals
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
